Related Experiment Video

Updated: Aug 9, 2025

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.0K

Correction to: Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis

Esperanza Pato-Cour1, Mª Auxiliadora Martin-Martinez2, Lara Borrego-Sanz3

  • 1Rheumatology Department and Health Research Institute (IdISSC), Hospital Clínico San Carlos, C/ Profesor Martin Lagos s/n, 28040, Madrid, Spain. esperanza.pato@salud.madrid.org.

Ophthalmology and Therapy
|February 22, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

2.8K
Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent
06:46

Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent

Published on: May 8, 2017

8.9K

Related Experiment Videos

Last Updated: Aug 9, 2025

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.0K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

2.8K
Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent
06:46

Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent

Published on: May 8, 2017

8.9K

Related Concept Videos

Therapeutic Index01:13

Therapeutic Index

4.5K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.5K
Inflammatory Response I: Vascular and Cellular01:30

Inflammatory Response I: Vascular and Cellular

11.9K
The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
11.9K

Articles linked to this work by shared authors, journal, and citation graph.

Association of serum adalimumab levels and immunogenicity with clinical response in non-infectious uveitis: a real-world cohort study.

Frontiers in immunology·2026

Therapeutic management of axial spondyloarthritis: summary of 2024 update of the Spanish clinical practice guideline (ESPOGUIA).

Therapeutic advances in musculoskeletal disease·2026

Vascular endothelial growth factor inhibitors outcomes in good vision eyes with neovascular age-related macular degeneration: Fight Retinal Blindness! SPAIN Report 4.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026

Determinants of Non-infectious Scleritis Complications and Their Impact on Visual Outcome: Results from the International AIDA Network Scleritis Registry.

Ophthalmology and therapy·2026

Secondary punctate inner choroidopathy in an RP2 associated retinopathy female carrier.

Journal of ophthalmic inflammation and infection·2026

Cardiorenal Biomarkers and Cerebrovascular Risk in Patients with Congenital Heart Disease.

Journal of clinical medicine·2026

Is Kmax a Reliable Endpoint for Evaluating Outcomes after CAIRS?

Ophthalmology and therapy·2026

Three-year Comparative Efficacy and Safety of Repeated Low-level Red-light Therapy and Orthokeratology for Myopia Control in Children.

Ophthalmology and therapy·2026

High-Risk Characteristics of Eyelid Basal Cell Carcinoma in Young Patients: A Retrospective Cohort Study.

Ophthalmology and therapy·2026

Acellular Bowman Layer and Descemet Membrane Allografts for Non-Ectatic Anterior Corneal Diseases: A Narrative Review of Emerging Evidence.

Ophthalmology and therapy·2026

Selecting Vehicle Comparators in Dry Eye Disease Clinical Trials: Implications for Efficacy and Safety Assessment and Regulatory Outcomes.

Ophthalmology and therapy·2026

Effect of Photobiomodulation‑Based LED on Myopia Control in Children: An Exploratory Randomized Clinical Trial.

Ophthalmology and therapy·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us